Prosecution Insights
Prosecution Insights
6 pending office actions • 1 client • 4 examiners • 4 art units • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| No statute on record | 4 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHESTNUT, BARRY A | 2 | 73.5% | +5.9% |
| LARA, CAROLINE MONSERRAT | 2 | — | — |
| PAK, YONG D | 1 | 74.4% | +13.7% |
| RYAN, DOUGLAS CHARLES | 1 | 40.0% | +48.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18012094 | LNP COMPOSITIONS COMPRISING MRNA THERAPEUTICS WITH EXTENDED HALF-LIFE | RYAN, DOUGLAS CHARLES | 16d overdue |
| 17928680 | PHENYLALANINE HYDROXYLASE VARIANTS AND USES THEREOF | PAK, YONG D | 75d |
| Client (Assignee) | Pending OAs |
|---|---|
| Moderna | 6 |
| Art Unit | Apps |
|---|---|
| 1672 | 2 |
| 1633 | 2 |
| 1652 | 1 |
| 1635 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18286705 | EPSTEIN-BARR VIRUS MRNA VACCINES | Modernatx, Inc. | CHESTNUT, BARRY A | 1672 | Other | Non-Final OA | 2d overdue | Pending | Oct 12, 2023 |
| 18282097 | THERAPEUTIC USE OF SARS-COV-2 MRNA DOMAIN VACCINES | Modernatx, Inc. | CHESTNUT, BARRY A | 1672 | §103 | Non-Final OA | 17d overdue | Pending | Sep 14, 2023 |
| 17928680 | PHENYLALANINE HYDROXYLASE VARIANTS AND USES THEREOF | Modernatx, Inc. | PAK, YONG D | 1652 | DPOther | Final Rejection | 75d | Pending | Jul 18, 2023 |
| 18012094 | LNP COMPOSITIONS COMPRISING MRNA THERAPEUTICS WITH EXTENDED HALF-LIFE | Modernatx, Inc. | RYAN, DOUGLAS CHARLES | 1635 | Other | Non-Final OA | 16d overdue | Pending | Dec 21, 2022 |
| 17925125 | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION, AND METHODS OF USING THE SAME FOR TREATING COVID-19 | Modernatx, Inc. | LARA, CAROLINE MONSERRAT | 1633 | Other | Non-Final OA | 22d overdue | Pending | Nov 14, 2022 |
| 17925114 | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION | Modernatx, Inc. | LARA, CAROLINE MONSERRAT | 1633 | Other | Non-Final OA | 16d overdue | Pending | Nov 14, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial